Review Articles

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300

Oppel B.W. Greeff, Jacob John van Tonder, Kershlin Naidu, Alicia McMaster, Alet van Tonder, Rashem Mothilal
South African Family Practice | Vol 60, No 4 : July/August| a4903 | DOI: https://doi.org/10.4102/safp.v60i4.4903 | © 2019 Oppel B.W. Greeff, Jacob John van Tonder, Kershlin Naidu, Alicia McMaster, Alet van Tonder, Rashem Mothilal | This work is licensed under CC Attribution 4.0
Submitted: 25 October 2019 | Published: 28 August 2018

About the author(s)

Oppel B.W. Greeff, University of Pretoria, South Africa
Jacob John van Tonder, Triclinium Clinical Development (Pty) Ltd, South Africa
Kershlin Naidu, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, South Africa
Alicia McMaster, Sanofi-Aventis South Africa (Pty) Ltd, South Africa
Alet van Tonder, Sanofi-Aventis South Africa (Pty) Ltd, South Africa
Rashem Mothilal, Sanofi-Aventis South Africa (Pty) Ltd, South Africa

Full Text:

PDF (154KB)

Abstract

Glucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences confound comparison of results from different glucose clamp studies. The first part of this series on glucose clamp studies discussed practical tips for the interpretation of glucose clamp studies. The second part of the series compares the PK/PD profiles of longer-acting basal analogue insulins, insulin degludec (IDeg) and insulin glargine U300 (Gla-300). The patient populations for glucose clamp studies with these analogue insulins differ, and therefore direct comparison of the data is not always possible. The maximum duration of action of IDeg is reported as 42 h and that of Gla-300 as 36 h, translating to 24 h coverage. The plasma insulin concentration of IDeg is 56 times that of Gla-300. Results from phase III clinical trials for these analogue insulins confirm the predictability and low within-subject variability observed in glucose clamp studies. Insight into the PK/PD profiles of longer-acting basal analogue insulins allows the treating physician to utilise these characteristics to optimise the treatment of their patients with diabetes.

Keywords

analogue insulins; glucose clamp; time–action profile; pharmacokinetics; pharmacodynamics

Metrics

Total abstract views: 1340
Total article views: 479


Crossref Citations

No related citations found.